Dedication.....................................................................................................................................................................................ixPreface........................................................................................................................................................................................xiChapter One Too Many Radicals ... Too Many Failures............................................................................................................................................1Chapter Two Everything You Ever Wanted to Know About Chronic Prostatitis.......................................................................................................................26Chapter Three Chronic Disease Management.......................................................................................................................................................56Chapter Four Definitive Treatment for Prostate Cancer Targets All Men with the Disease ... Inappropriately.....................................................................................85Chapter Five You Are What You Eat..............................................................................................................................................................101Chapter Six The 'Dirty Little Secret' Doctors Won't Tell You ... 'Prostate Biopsies Really Do Spread Prostate Cancer cells'....................................................................119Chapter Seven Andropause (Male Menopause)......................................................................................................................................................130Chapter Eight Testosterone Replacement or Supplementation Poses High Risk for Prostate Cancer in the Aging Male................................................................................137Chapter Nine Prostate Cancer Diagnosis in Chaos................................................................................................................................................145Chapter Ten Controversies associated with prostate health and beyond...........................................................................................................................151Chapter Eleven Controversial Male Health Studies from the Literature...........................................................................................................................164Chapter Twelve Pathology of Prostate Cancer....................................................................................................................................................183Chapter Thirteen Is it Necessary to Cure Prostate Cancer when it is Possible?..................................................................................................................212Chapter Fourteen High-intensity Focused Ultrasound for Prostate Cancer: 2006 Technology and Outcome Update.....................................................................................228A Glossary of Prostate Cancer Related Terms & Abbreviations....................................................................................................................................245References.....................................................................................................................................................................................339–356Appendix—1 ProCap Trial—A Prostate Cancer Prevention Trial.........................................................................................................................357Appendix—2 Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.............................................................................365Appendix—3 New European Study Confirms Effectiveness of PSA Test.........................................................................................................................367Appendix—4 Dr. Wheeler's Commentary to US Preventive Services Task Force (USPSTF)........................................................................................................370Appendix—5 Adult Urology.................................................................................................................................................................373Appendix—6 Men's Health is in Chaos......................................................................................................................................................375Appendix—7 Patient questionnaire response: Prostate Biopsy Exposed.......................................................................................................................380Appendix—8 Dr. Schoenberg's proclamation letter related to HIFU..........................................................................................................................382Appendix—9 Unintended Deception— Observations by Dr. Wheeler.......................................................................................................................387Appendix—10 Endorectal MRI found valuable prior to salvage RP............................................................................................................................390Appendix—11 Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?.............................................................393Appendix—12 A Brief Description of the Ultimate Prostate Scan (UPS)—Targeting Disease ... 'One Patient at a Time'..................................................................416Appendix—13 Chronic Disease Management may be the best "first choice" when prostate cancer is diagnosed and if quality of life is important to you!......................................419Appendix—14 Why HIFU Fails...............................................................................................................................................................422Appendix—15 Heidelberg Working Group for biopsy-free diagnosis established: Decreasing the risks of prostate cancer diagnosis............................................................431Appendix—16 Long-Term Pca Control with RP is 'Excellent'.................................................................................................................................434Appendix—17 Chronic Disease Management (CDM) is a unique treatment concept that integrates traditional medicine and complementary medicine...............................................437Appendix—18 Is VB3 an Acceptable Diagnostic Alternative to EPS?..........................................................................................................................461Appendix—19 IPSS—Index Aua (BPH) Symptom Score.....................................................................................................................................464Appendix—20 Cigna Healthcare Coverage Position...........................................................................................................................................468Appendix—21 My story in brief: The clinical events in the life of Greg O'Haver...........................................................................................................489Appendix—22 My Battle To Survive Prostate Cancer.........................................................................................................................................494Appendix—23 Bryce Zender's Story.........................................................................................................................................................500Appendix—24 Ray Cunningham's Story.......................................................................................................................................................508Appendix—25 Chronic Disease Management—A Worldwide Prostate Cancer Strategy........................................................................................................512Appendix—26 Benign Prostatic Hyperplasia (BPH)...........................................................................................................................................523Appendix—27 Avoiding Prostate Biopsies is now 'State of the Art'.........................................................................................................................532Appendix—28 Biopsy Procedures are on the Rise............................................................................................................................................538Appendix—29 Jim Little's story – to his friends at the Prostate 90 chat group......................................................................................................551Appendix—30 Jack Mosier's Story..........................................................................................................................................................557Appendix—31 Letter discussing the care of Jerry Deplazes.................................................................................................................................563Appendix—32 The 8 Phrases you never want to hear from your Doctor:.......................................................................................................................566Appendix—33 For Immediate Release Aventura, Florida......................................................................................................................................569Appendix—34 Rectal wall recurrence of prostate carcinoma.................................................................................................................................572Appendix—35 Robotic Prostatectomy—A Race to Failure?...............................................................................................................................577Appendix—36 Benefits of Green Tea versus Prostate Cancer.................................................................................................................................596Appendix—37 Effects of Dietary Changes on Prostate Cancer Growth.........................................................................................................................598Appendix—38 Synopsis of Professional Achievements (Curriculum Vitae).....................................................................................................................600Appendix—39 Data Regarding Benefit of the Peenuts formula on the White blood cell count of the Expressed Prostatic Secretion (EPS); a consecutive series of patients.....................606Appendix—40 Data regarding PSA variation following the use of the Peenuts Formula at varying intervals...................................................................................610Appendix—41 Data regarding the varying improvement of Voiding Symptoms with the continuous use of the Peenuts Formula of 6-12 months or longer...........................................615

Chapter One

Too Many Radicals ... Too Many Failures

When you hear the news that you have prostate cancer, what are you going to do? Rather than panic, you must accept the facts and begin the learning process. Your exit strategy from this dilemma will be to determine how your cancer will be managed. Proven treatment options range from a conservative management program of diet, wellness management, antioxidants and specific nutritional supplements we call chronic disease management (CDM) with no impact on your quality of life to radical surgery with a major impact. Deciding how you will treat your prostate cancer will become the single most important decision you will make for the remainder of your life. Ultimately, your decision must be acceptable to you and your family and be effective while minimizing undue risk, complications and side effects.

Prostate cancer is a disease that does not discriminate, wreaking havoc on all men irrespective of age, ethnicity, education, financial or social status. When it comes to the topic of prostate cancer, all men are equally ignorant, regardless of education (obviously excepting doctors who should know the topic better than the public at large). Prostate disease in general and prostate cancer specifically is the most common and dominant disease that men face, while representing a diseased organ that must be understood and dealt with by men of all ages. Often times referred to as a disease of healthy men, prostate cancer has no boundaries, no conscience and will strike most time with no warning other than an elevated prostate specific antigen (PSA) blood test. Your only defense is to become educated on the disease, get motivated and proactive. Your goal is to maintain an optimal PSA of less than 1.0 ng/ml. Many men who fail to heed this warning will pay the ultimate price with their lives. Many more will be spared but asked to endure a life of subtraction, losing many of the qualities from life that make being a man so special.

Statistics on Prostate Cancer

While prostate disease is arguably the number one health risk that men face, prostate cancer is the most prolific organ cancer that men acquire in their lifetime as well as the second leading cause of cancer death, behind lung cancer. One in five to six men will be diagnosed with prostate cancer in their lifetime. Prostate cancer occurs most often in older men. African-American men have a rate of prostate cancer that is twice their Caucasian counterparts. According to the American Cancer Society, an estimated 218,890 men will be diagnosed with prostate cancer this year while in excess of 27,000 men will die from the disease. This translates into a new case of prostate cancer diagnosed every three minutes while a man dies from the disease every 16 minutes of every day. With the baby boomer generation aging into their 50s and 60s, at 5,000 men per day; the expectation is for 50,000 men to lose their lives annually from prostate cancer by the year 2020. While men in their 60s or older experience the news that prostate cancer has been detected most frequently, data shows 30 percent of 30-year-old men will acquire the disease only to have their lives spared initially as the cancer incubates for upwards of 15 to 20 years before the impact is realized with a rising PSA blood test. When you decide to become motivated to learn more about this disease is your decision; what you learn about the disease and how you treat the disease is the heart and soul of this book.

Radical Prostatectomy—'Gold Standard' or Educated Guess

Historically, radical prostatectomy (total surgical prostate removal) has been the most common treatment offered and rendered when prostate cancer is diagnosed. The irony of treating the most prolific male cancer most frequently with radicalp rostatectomy is that the failure rate will be unacceptably high while essentially equal regardless of the approach utilized including the DaVinci Robot technique. While prostate cancer is being detected earlier, there is no convincing data to suggest a significant survival advantage of radical prostatectomy over brachytherapy (radioactive seed implants), as example, with or without external beam radiation, cryosurgery or a treatment strategy called chronic disease management (CDM) (refer to the CDM chapter for a comprehensive review of this concept). In other words, there is significant data to suggest alternative therapies like CDM may make a better first choice of treatment if overall survival is relatively unaffected by the specific therapy selected. Why should you undergo a major radical surgery with significant complications and side effects if it's not going to make a difference in your survival? You should not!

If 10 men with prostate cancer are lined up and evaluated, doctors cannot reliably predict who will ultimately be cured and who will fail. In my opinion, this is primarily due to a lack of discrimination regarding where the disease is actually located; principally, the extent of disease. Patients showing more favorable disease characteristics may have better survival rates, but the fact remains that we cannot predict the final outcome of treatment. Some patients with "good" cancers will perish of prostate cancer regardless of any treatment we can offer, and some with "bad" or very aggressive cancers may survive even with minimal treatment. Until we have better tools (or utilize better tools, not currently accepted) that allow us to make truly reliable predictions, the best we can say is that radical prostatectomy can possibly cure 60-70 percent of prostate cancer patients. To state more clearly, we can't accurately predict who will be cured and who won't be cured using our present diagnostic and treatment modalities. To be sure, regardless of our surgical skill level, the outcome and cure rate from major radical prostate surgery is unpredictable. This point is validated by Hendrick Isbarn, M.D. and collaborators at the University Hospital Hamburg-Eppendorf in Hamburg, Germany in their research published in the British Journal of Urology (International Edition) in 2009. Specifically, they found that the biochemical recurrence (BCR) rate for prostate cancer was 40% at 10 years. Unfortunately, this is an unacceptably high rate of prostate cancer recurrence; representative of all radicals performed worldwide, in my opinion.

So why is radical prostatectomy performed so often? While this is a great question, the answer is very elusive. We hear phrases like, "that's what I was trained to do," "it's the 'Gold Standard' in prostate cancer treatment," "and it's the only way that we can be sure that all of the cancer is gone" or "this procedure gives you the best chance for a cure." When a patient asks a doctor for his best recommendation and the only procedure he performs is a radical prostatectomy, what do you expect him to say? Even if the doctor also performs seed implantation therapy and cryosurgery but believes the radical approach is best for most patients; do not expect him to give a glowing endorsement for either of the other two choices. While doctors are supposed to be unbiased in their approach, it is difficult for most physicians to remain completely objective. It's not their fault. They are just expressing what they know based on their training and experience. The Hippocratic Oath states, "We must first do no harm." This should still be the starting point for any decision related to treatment of prostate cancer. Finally, remember that treating prostate cancer is also a business. The insurance industry rewards some treatments substantially more than others. Physicians are only human and will tend to be influenced by the very high financial rewards from the insurance industry for surgery or radiation therapy over conservative treatments that aren't reimbursed well. Furthermore, physicians may own shares of radiation therapy centers that are highly reimbursed by Medicare and most insurance companies. Even given their best intentions, it's hard for many physicians to be totally objective in their recommendations when they can earn $20,000 or more per patient by referring you to their radiation center.

Physician Practice Patterns

In a survey of more than 500 urologists reported on in the Journal of the American Medical Association (JAMA), the question was asked of urological surgeons; what approach should be taken with a 65-year-old male with a newly diagnosed prostate cancer associated with a Gleason score of 7 and a PSA less than 10 ng/ml? For those unfamiliar with the meaning of Gleason score, refer to the glossary and/or the pathology section of this book for a review. For those more familiar with the term, a Gleason score of 7 represents a moderate to poorly differentiated cell type, commonly encountered in approximately 30-35 percent of all cases of prostate cancer. To the surprise of no one, a traditional urology line of thought or 'party line' was endorsed by 90 percent of the urologists polled, thereby recommending a radical prostatectomy for this patient. While this opinion from a surgeon may come as no surprise, there is minimal documentation to support the strength of such an opinion.

In an effort to establish diversity of opinion, noting that doctors would only recommend what was best for the patient; radiation oncologists were asked their recommendation for the same patient scenario with the same cancer characteristics. The majority of radiation oncologists followed the dictum of their residency-training manual and recommended brachytherapy (radioactive seed implantation) or external beam radiation or a combination of both. Patients, who seek these professional opinions, must be mindful that it may be difficult to get a totally objective opinion from a physician who is biased based on how he was trained and how he practices. It is often said and bears restating; "If all you have is a hammer, it is amazing how everything begins to look like a nail."

In this imperfect world, the burden for an improved understanding of the disease and its various treatments, unfortunately, becomes the responsibility for each patient, individually; notwithstanding their lack of adequate education. This doesn't seem quite fair to the vulnerable patient doing little to diminish the anxiety experienced when the diagnosis is made. Based on a likely rush to judgment that is commonly experienced when the diagnosis of prostate cancer is made, patients are encouraged to become increasingly aware of the peril and consequences associated with prostate cancer treatment prior to the diagnosis, not after.

Taking the time to evaluate your options is supported by a research study performed at Johns Hopkins Medical Center. What they demonstrated is that while the diagnosis of prostate cancer must be taken seriously, a delay in treatment of months or even years may not change the course of the disease and the outcome. While this will likely depend on the specific characteristics of disease identified in a given patient, the news is nonetheless heartening as the task to fully understand the disease and the various treatment options is significant. It will take a concerted effort and ample time by all who choose to be well versed.

Better Imaging, Better Decisions, Better Results

This book intends to serve the many worried men with prostate cancer and their families as a fair and objective resource to help in understanding the disease you are now facing and the options available to you. By taking a fresh look at the available scientific information and explaining it in a new and unique way, it's our intention to help you make a truly informed decision about your treatment choices and ultimately about your future.

The true nature of the disease must be completely understood before any meaningful decision is made on how to proceed when the diagnosis of prostate cancer is made. While it is critical to determine the extent of disease in order to select the best treatment strategy, it is equally important to realize the severe limitations of our present diagnostic process based upon our current outdated imaging tools and biopsy techniques. For this reason, we are very excited about Magnetic Resonance Imaging with or without Spectroscopy (MRI or MRIS) discussed in more detail later and throughout this book. MRI performed with a 3.0 Tesla magnet or equivalent alternative may well be the best diagnostic modality for the detection of prostate cancer prior to a biopsy or to establish true organ confinement once the diagnosis of prostate cancer has been confirmed by a biopsy. Intuitively, imaging must be done before a biopsy (if a biopsy ever makes sense); not after. The 3 Tesla MRI, diagnostic modality provides the most accurate cancer imaging technology available. The outstanding image quality ensures the best chance for realistic decision-making leading to ultimate success. This scan, which we call the "Ultimate Prostate Scan," provides precision prostate cancer localization allowing us to determine whether the tumor is truly organ-confined prior to any proposed therapy. If organ confinement is not reliably established, the scientific data does not support radical surgical removal of the prostate. The MRI Scan provides a true road map of objective imaging excellence to validate cancer localization while spectroscopy, when utilized as an additional sequence, allows us to understand the biochemical components of the tissue in question. Together, these scan sequences are integral to changing the paradigm relevant to the diagnosis and subsequent treatment of prostate cancer.

Chronic Disease Management

Prospective study data associated with our research treatment protocol evaluated the benefit of diet and nutrition versus prostate cancer. The study, entitled, "Is it necessary to cure prostate cancer when it is possible," represented in the Journal, Clinical Interventions in Aging, supports the concept of allowing men the opportunity to live with prostate cancer much like patients would live with diabetes or arthritis rather than undergo surgical organ removal or radiation. If men decide later to attempt to cure the disease with surgery or radiation, their chance of success should not have been significantly diminished by the delay. In other words, taking our time to evaluate all issues related to the diagnosis and treatment of prostate cancer allows us to avoid a rush to judgment. Quite frankly, by delaying the definitive decision making, anxiety is reduced and the advantages and disadvantages of every therapy can be studied in more detail and become better known. You cannot fully appreciate the consequences of your treatment decision until you completely understand the lifestyle you will have to accept when the choice is made.

The key to the success of our research treatment protocol relates to the ability to suppress or resolve the signs and symptoms of inflammation (non-bacterial prostatitis) through diet and a prostate-specific patented dietary supplement we developed called Peenuts®. This formula represents a unique and synergistic blend of vitamins, minerals, herbs and amino acids. Its special ability to reduce prostatic inflammation has been scientifically validated by improvements in white blood cell counts (a universal sign of inflammation) associated with the prostate secretion or expressed prostatic secretion (EPS) obtained at the time of digital prostate exam, as well as a decrease in PSA levels, given its success with widespread use as a stand-alone treatment for prostatitis. While diet plays an important role, the road to success without surgery or radiation requires optimizing all of our dietary and nutritional resources to fight the cancer. This will become quite apparent once you have reviewed the dietary and nutritional sections of this book.

In our prospective study, mentioned above, 30 patients with known prostate cancer were evaluated over an average time frame of 49 months. During this time, their only treatment was dietary modification and our scientifically designed prostate anti-inflammatory supplement Peenuts®. By the end of the study, 28 out of the 30 patients noted a marked improvement or decrease in their PSA levels (the recognized marker of prostate cancer disease activity) averaging 55 percent. This degree of improvement is truly remarkable and has never been reported before in such a large study group without using hormonal therapy, surgery or radiation. While we are certainly pleased with the outcome, we were not really surprised, as we have noted similar significant improvements in thousands of patients over the years while using this supplement. This concept of nutritional optimization and chronic disease management has not been studied adequately as it has never received priority funding. It is our hope that visionary philanthropists who understand and embrace our beliefs, will come together to provide the capital necessary to validate our research as well Study (PROCAP Trial), touched on above, will be described in this entirety in the Appendix.

(Continues...)

Excerpted from MEN AT RISKby Ronald E. Wheeler Copyright © 2012 by Ronald E. Wheeler, M.D.. Excerpted by permission of AuthorHouse. All rights reserved. No part of this excerpt may be reproduced or reprinted without permission in writing from the publisher.
Excerpts are provided by Dial-A-Book Inc. solely for the personal use of visitors to this web site.

"About the title" may belong to another edition of this title.

PBShop.store US

Wood Dale, IL, U.S.A.

5-star seller

AbeBooks seller since April 7, 2005

Shipping rates within U.S.A.

Item	7 to 14 business days	7 to 14 business days
First item	£ 0.00	£ 0.00

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Payment methods

Store description

We first started out as “The Paperback Exchange,” a chain of physical bookstores where we would part exchange your beloved books for new stories to transport you to faraway places. However, as shopping started to evolve to online shops and marketplaces, we bid our stores goodbye to become “PBShop.” This transition has only allowed us to blossom as we now ship thousands of titles to book lovers across the globe. We pride ourselves in being a community of local book lovers which allows our passion and devotion to shine in everything we do. In 2020 we not only celebrated our 20th birthday but our 1st birthday as being completely employee owned after becoming an E.O.T in September 2019. We are proud to be different and embrace standing apart on a book mountain by working from a virtual inventory which allows us to provide thousands of books that may be difficult to get for your bookshelf or your studies. Working with a number of different suppliers allows us to explore other avenues such as puzzles, sheet music and even stationery so we really do have something for everyone. Life is about being versatile in all realms of existence. If this is your first visit or you are a returning customer, we would like to welcome you to the PBShop family, for there is no friend as loyal as a book. We are a company who put our customers at the centre of everything we do as we understand the importance of reading because once you learn to read, you will forever be free. There are a whole lot of things in this world of ours that we are yet to explore, which is why we will forever inspire curious minds.…

Specialty

Hardbacks, Paperbacks

Seller's business information

Pbshop.co.uk Ltd

Unit 22 Horcott Industrial Estate, Horcott Road
Fairford, United Kingdom GL7 4BX

Contact sellerView this seller's itemsView seller's storefront

Terms of sale

Returns Policy
We ask all customers to contact us for authorisation should they wish to return their order. Orders returned without authorisation may not be credited.
If you wish to return, please contact us within 14 days of receiving your order to obtain authorisation.

Returns requested beyond this time will not be authorised.

Our team will provide full instructions on how to return your order and once received our returns department will process your refund.
Please note the cost to return any unwanted order to us is borne by the buyer.

Should your order arrive damaged, not as advertised or faulty, we must be advised of this within 14 days of delivery. Please contact us so we can find the best solution for you.

Our Customer Care Team can be contacted via emailing paperback-us@paperbackshop.co.uk, or by calling our UK Office on +441285 712 917. We are available 9:00am till 5:30pm GMT weekdays and 9:00am till 1:00pm GMT on Saturdays.

Right of withdrawal

If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.

Information regarding the right of withdrawal

Statutory right to withdraw

You have the right to withdraw from this contract within 14 days without giving any reason.

The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.

To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.

To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.

Effects of withdrawal

If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).

We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.

We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.

You shall send back the goods or hand them over to PBShop.store US, Springfield Gardens, New York, U.S.A., +44 1285 712917, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.

Exceptions to the right of withdrawal

The right of withdrawal does not apply to:

The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.

Shipping terms

Books are shipped from our US or UK warehouses. Delivery estimates allow for delivery from either location.

Privacy and security

We are committed to protecting the privacy and security of personal data. This policy tells you how we will collect and use your personal data, and what you should expect in respect of the personal information about you that we have collected.

We are PBShop.co.uk Limited (registered in England & Wales with Company No: 9366362). Our registered office is at Swatton Barn, Badbury, Swindon, SN4 0EU, United Kingdom.

The person with responsibility for our data protection compliance is the Managing Director and they can be contacted via email at help@pbshop.store.

We are the data controller of the personal data that we keep and use, and we are therefore responsible for making sure that our systems, processes and people comply with the relevant data protection laws in respect of that personal data.

We will act in respect of personal data to comply with the six principles of the General Data Protection Regulation (“GDPR”), which are:

Lawfulness, fairness and transparency;
Purpose limitation;
Data minimisation;
Accuracy;
Storage limitation;
Integrity and confidentiality.
You have rights in respect of how your personal data can be processed; these include the right to request:

a copy of your personal data;
that inaccurate data is rectified; and
that your personal data is, in certain circumstances, erased or restricted.
You have the right to complain to the Information Commissioner, which you can do by contacting the Information Commissioner’s Office (ICO) directly. Full contact details, including a helpline number, can be found on the ICO website (www.ico.org.uk). This website also has useful information on your rights and our obligations. However, please raise any concerns or issues with us first so that we may deal with this as quickly as possible for you.

COLLECTION, USE AND DISCLOSURE OF PERSONAL DATA
We collect and process data for the following reasons:

personal data collected and created in relation to our selling books and other items; and
personal data relating to our people (which means those people working for our company, or providing services to us, or potentially working or providing services to us, including employees, consultants, temporary or casual workers and contractors).
All of our people are required to abide by our Privacy Policy when handling personal data, and are provided with appropriate data protection training. Any breach of data protection will be taken seriously, and may result in disciplinary action.

Selling books and other items
COLLECTION:
We will collect personal information which may include names, addresses and other information for our customers. This will be done for the management of the commercial relationship with our customers.

We may collect this personal data from you directly, and also from third parties, including publicly available third party sources. Additional personal data will be collected as it is created by or supplied to us in the course of anything we do for you.

USE:
We will use the personal data in the course of making sales and to comply with requirements that we are required to undertake.

We will only use your personal data when the law allows us to. Most commonly, we will use your personal data in the following circumstances:

in performance of a contract (the agreement to sell books and other items); and/or
compliance with a legal obligation; and/or
vital interests of the data subject; and/or
where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests.
We may also use your personal data in the following situations, which are likely to be far less common:

where we need to protect your interests (or someone else’s interests);
where it is needed in the public interest or for official purposes.
DISCLOSURE:
We may share personal data with third parties as is necessary in the sale of books and other items, including to third party providers who deliver services to support the operation of our company.

In respect of all disclosures of personal data, we will only share the personal information which is necessary for the particular purpose for which it is provided, or where we have another legitimate interest in doing so, and we will ensure that the personal data is appropriately protected.

RETENTION PERIOD:
We will keep personal data only for as long as is necessary to fulfil the purposes for which we collected it, including for the purposes of satisfying any legal, accounting or reporting requirements. Normally, our retention period for personal data collected for this purpose is a minimum of 6 years after the end of the period that we are selling books and other items.

Our people
COLLECTION:
We will collect names, addresses, contact details, education and employment history, identity and other background checks (which may include appropriate criminal and financial checks and confirmation of the right to work in the UK), marital status and information on next of kin and dependents, financial information (such as bank details and NI numbers), date of birth, gender, a copy of your passport and driving licence, performance information and compensation history, recruitment information (including references), salary, benefits, pension and annual leave information, disciplinary and grievance information, photographs, information about your use of our information and communications systems and CCTV footage or other information obtained through electronic means.

We may collect and use special categories of personal data as required in the carrying out of obligations and exercising specific rights of us or the data subject in the field of employment. This may include information relating to matters such as health, racial origin, religious belief and offences or alleged offences.

Personal data may be collected from you during the selection process (for example via your application form and CV) and during your employment (including holiday forms, expense claims, performance reviews, any disciplinary or grievance processes), or from third parties, including referees, health service providers, background check providers.

USE:
Personal data of our people will be used for HR administration and management, both in respect of the selection of people to work for us (including suitability, eligibility and/or fitness to work), and those who do work for us, to include learning and development, disciplinary and security (of people, offices and data) requirements, providing and liaising with benefits providers, business management and planning (including accounting and auditing), paying you and dealing with tax and NI deductions, assessing and deciding on salary reviews and compensation, conducting performance reviews and managing performance, dealing with legal disputes involving you or others, preventing fraud, monitoring your use of our information and communications systems, ensuring compliance with our policies, and equal opportunities monitoring.

We will only use your personal data when the law allows us to. Most commonly, we will use your personal data in the following circumstances:

In performance of a contract with you; and/or
compliance with a legal obligation; and/or
vital interests of the data subject; and/or
where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests.
We may also use your personal data in the following situations, which are likely to be less common:

where we need to protect your interests (or someone else’s interests);
where it is needed in the public interest or for official purposes.
In respect of all disclosures of personal data, we will only share the personal information which is necessary for the particular purpose for which it is provided, or where we have another legitimate interest in doing so, and we will ensure that the personal data is appropriately protected.

In respect of special categories of personal data, we may process this in the following circumstances:

in limited circumstances with your explicit written consent; and/or
where we need to carry out our legal obligations and in line with our policies; and/or
where it is needed in the public interest (such as for equal opportunities monitoring or in relation to our occupational pension scheme), and in line with our policies; and/or
where it is needed to assess your working capacity on health grounds, subject to appropriate confidentiality safeguards.
Less commonly, we may process this type of information where it is needed in relation to legal claims or where it is needed to protect your (or someone else’s) interests and you are not capable of giving your consent, or where you have already made the information public. We may also process such information about our people (or former people) in the course of our legitimate business activities with the appropriate safeguards.

The special categories of personal data may be used in the following ways:

in relation to leaves of absence, to comply with employment and other laws;
in relation to your physical or mental health, or disability status, to ensure your health and safety in the workplace and to assess your fitness to work, to monitor, manage and administer benefits and absences;
in relation to your race, national or ethnic origin, religious, philosophical or moral beliefs, or your sexual life or sexual orientation, to ensure meaningful equal opportunity monitoring and reporting.
DISCLOSURE:
Personal data may be transferred to service providers who support the operation of our business (such as payroll service providers), to other third parties reasonably necessary in the conduct of our business (including insurers, professional advisors, regulators). These third parties may be acting as processor, or controller of personal data in their own right.

RETENTION PERIOD:
We will keep personal data only for as long as is necessary to fulfil the purposes for which we collected it, including for the purposes of satisfying any legal, accounting or reporting requirements. We will normally keep personal data of applicants who we do not employ for six months after we receive it.

We will keep personal data of employees throughout your employment and normally for a minimum of six years after your employment ends.

Changes to your personal data
It is very important that the personal information that we hold about you is accurate and current. Please tell us if your personal information changes during your relationship with us.

Data Security
We have put in place measures to prevent your personal data from being accidentally lost, used or accessed in an unauthorised way, altered or disclosed. In addition, we limit access to your personal data to those of our people and other third parties who have a business need to know. They will only process your personal data on our instructions and where they have agreed to treat the information confidentially and to keep it secure. We have put in place procedures to deal with any suspected data security breach and will notify you and the ICO of a suspected breach where we are legally required to do so.

Where we store your personal data
We principally store data, both electronically and on file, at our office.

Personal data may be transferred outside of the EEA by processors acting on our behalf. For transfers to countries not considered adequate by the EC, we will ensure that personal data is adequately protected, as required by the GDPR. This would include by use of the Standard Contractual Clauses adopted by the EC to protect personal data.

Your rights
Under certain circumstances, you have the right by law to request:

access to your personal data. This enables you to ask to receive a copy of the personal data that we hold about you and to check that we are lawfully processing it.
correction of the personal data that we hold about you.
erasure of your personal data.
object to processing of your personal data where we are relying on our legitimate interest and there is something about your particular situation which makes you want to object to processing on this ground. You also have the right to object where we are processing your personal information for direct marketing purposes.
restriction of processing of your personal data.
transfer of your personal data to another party.
Links from our website
Our website may, from time to time, contain links to and from the websites of third parties that we permit to make such links. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. We recommend that you check these policies before you submit any personal data to these websites.

CHANGES TO THIS PRIVACY POLICY
Any changes we may make to our privacy policy in the future will be posted on our website, so please ensure that you are viewing the correct version.

Please contact us if you have any questions, comments or requests regarding this Privacy Policy.

Last amended May 2021.

Men At Risk

Item description from seller

Bibliographic details

Synopsis

About the title

Excerpt. © Reprinted by permission. All rights reserved.

MEN AT RISK

AuthorHouse

Contents